Edwards Lifesciences announces presentation of one-year SAPIEN 3 data
Edwards Lifesciences (EW) announced one-year data highlighting the continued performance of its SAPIEN 3 Ultra RESILIA valve. The data were ...
Edwards Lifesciences announces positive results in one year TAVI trial
Designed for patients needing a replacement valve, the company’s TAVI trial has found low rates of mortality after a year of ...
Hold Rating Maintained on Edwards Lifesciences Despite Positive SAPIEN 3 Ultra RESILIA Valve Data
Analyst Josh Jennings from TD Cowen maintained a Hold rating on Edwards Lifesciences (EW – Research Report) and keeping the price target at ...
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
LONDON--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London ...
MassDevice14h
Edwards reports ‘excellent’ outcomes for Sapien 3 Ultra Resilia TAVR system
Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...
GSA Capital Partners LLP Invests $481,000 in Edwards Lifesciences Co. (NYSE:EW)
GSA Capital Partners LLP bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) in the third ...
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of “Hold” from Brokerages
Edwards Lifesciences Co. (NYSE:EW – Get Free Report) has been given a consensus recommendation of “Hold” by the twenty-six ratings firms that are covering the firm, MarketBeat reports. Sixteen ...